AR055094A1 - Formulacion farmaceutica de nitrooxiderivados de nsaid - Google Patents
Formulacion farmaceutica de nitrooxiderivados de nsaidInfo
- Publication number
- AR055094A1 AR055094A1 ARP060103209A ARP060103209A AR055094A1 AR 055094 A1 AR055094 A1 AR 055094A1 AR P060103209 A ARP060103209 A AR P060103209A AR P060103209 A ARP060103209 A AR P060103209A AR 055094 A1 AR055094 A1 AR 055094A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- ono2
- group
- compound
- integer
- Prior art date
Links
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title abstract 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229910004679 ONO2 Inorganic materials 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 3
- 239000004094 surface-active agent Substances 0.000 abstract 2
- 125000003031 C5-C7 cycloalkylene group Chemical group 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000003262 carboxylic acid ester group Chemical class [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicacion 1: Una formulacion farmacéutica caracterizada porque comprende a) una o más NSAID que liberan NO de formula (1) M-C(= O)-O-X-ONO2, b) uno o más agentes tensioactivos, donde la relacion agente tensioactivo NSAID que libera NO se encuentra entre 0,1:1 y 10:1; c) un compuesto secuestrante de carbonilo seleccionado entre formas ácidas libres, sales, derivados de ésteres de ácidos carboxílicos del compuesto de formula (2) H2N-(CH2)m-(C6H4)-COOH donde m =0-10 y la cantidad del compuesto de formula (2) se encuentra entre aproximadamente 0,01 % y aproximadamente 5% en peso del peso total de la composicion; donde en la formula (1) M se selecciona del grupo formado por los restos de formulas (3); X es un espaciador, es decir, un compuesto que forma un puente entre el grupo donor de oxido de nitrogeno y la NSAID, y es seleccionado entre: i) alquileno C1-20 lineal o ramificado, preferentemente C1-10, opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo formado por: átomos de halogeno, hidroxi, -ONO2 o T, donde T es -OC(O)(C1-10 alquil)-ONO2 o - O(C1-10 alquil)-ONO2; ii) grupo cicloalquileno C5-7 opcionalmente sustituido con grupo alquilo C1-10 lineal o ramificado, preferentemente CH3; iii) un compuesto de la formula (4) donde n es un numero entero entre 0 y 20, preferentemente entre 0 y 5; y n1 es un numero entero entre 1 y 20, preferentemente n1 es un numero entero entre 1 y 5; con la condicion de que el grupo -ONO2 de formula (1) se encuentre unido a -(CH2) n1; y iv) -(CH(R2)-CH2-X2)n3-CH(R2)-CH2-, -(CH2-CH(R2)-X2)n3-CH2-CH(R2)- donde X2 es -O- o -S-; n3 es un numero entero entre 1 y 6, preferentemente entre 1 y 4, y R2 es H o CH3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05106854 | 2005-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055094A1 true AR055094A1 (es) | 2007-08-08 |
Family
ID=37670077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103209A AR055094A1 (es) | 2005-07-26 | 2006-07-25 | Formulacion farmaceutica de nitrooxiderivados de nsaid |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8691869B2 (es) |
| EP (1) | EP1906938B1 (es) |
| JP (1) | JP5238499B2 (es) |
| KR (1) | KR101342910B1 (es) |
| CN (1) | CN101227896B (es) |
| AR (1) | AR055094A1 (es) |
| AT (1) | ATE485033T1 (es) |
| AU (1) | AU2006274098B2 (es) |
| CA (1) | CA2616508C (es) |
| CY (1) | CY1112023T1 (es) |
| DE (1) | DE602006017701D1 (es) |
| DK (1) | DK1906938T3 (es) |
| ES (1) | ES2354278T3 (es) |
| HR (1) | HRP20110025T1 (es) |
| IL (1) | IL188253A0 (es) |
| MX (1) | MX2008001213A (es) |
| NO (1) | NO20080983L (es) |
| NZ (1) | NZ564589A (es) |
| PL (1) | PL1906938T3 (es) |
| PT (1) | PT1906938E (es) |
| RU (1) | RU2406482C2 (es) |
| SI (1) | SI1906938T1 (es) |
| WO (1) | WO2007012539A2 (es) |
| ZA (1) | ZA200801009B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011209757A (ja) * | 2011-07-06 | 2011-10-20 | Rohto Pharmaceutical Co Ltd | コンタクトレンズケア方法及び組成物 |
| US9688607B2 (en) * | 2011-08-15 | 2017-06-27 | Research Foundation Of The City University Of New York | No- and H2S-releasing compounds |
| WO2013130625A1 (en) * | 2012-02-27 | 2013-09-06 | Basil Rigas | Phospho-ester derivatives and uses thereof |
| RU2657803C1 (ru) * | 2017-03-21 | 2018-06-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный университет" | Средство, обладающее противовоспалительным и анальгезирующим действием |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997033568A1 (en) * | 1996-03-12 | 1997-09-18 | Novartis Ag | Filled gelatin capsules having a reduced degree of cross-linking |
| TWI243672B (en) * | 1999-06-01 | 2005-11-21 | Astrazeneca Ab | New use of compounds as antibacterial agents |
| SE0000774D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| AU2003240536B2 (en) * | 2002-06-05 | 2007-11-15 | Ivax Pharmaceuticals, S.R.O. | Reduction of gelatin cross-linking |
| BR0313149A (pt) | 2002-07-31 | 2005-06-28 | Pharmacia Corp | Forma de dosagem farmacêutica capaz de manter estável o perfil de dissolução após armazenamento |
-
2006
- 2006-06-29 PT PT06777502T patent/PT1906938E/pt unknown
- 2006-06-29 WO PCT/EP2006/063672 patent/WO2007012539A2/en not_active Ceased
- 2006-06-29 CA CA2616508A patent/CA2616508C/en active Active
- 2006-06-29 ES ES06777502T patent/ES2354278T3/es active Active
- 2006-06-29 CN CN2006800272160A patent/CN101227896B/zh not_active Expired - Fee Related
- 2006-06-29 AU AU2006274098A patent/AU2006274098B2/en not_active Ceased
- 2006-06-29 AT AT06777502T patent/ATE485033T1/de active
- 2006-06-29 PL PL06777502T patent/PL1906938T3/pl unknown
- 2006-06-29 MX MX2008001213A patent/MX2008001213A/es active IP Right Grant
- 2006-06-29 RU RU2008104505/15A patent/RU2406482C2/ru active
- 2006-06-29 NZ NZ564589A patent/NZ564589A/en not_active IP Right Cessation
- 2006-06-29 SI SI200630878T patent/SI1906938T1/sl unknown
- 2006-06-29 DK DK06777502.3T patent/DK1906938T3/da active
- 2006-06-29 EP EP06777502A patent/EP1906938B1/en active Active
- 2006-06-29 JP JP2008523286A patent/JP5238499B2/ja not_active Expired - Fee Related
- 2006-06-29 DE DE602006017701T patent/DE602006017701D1/de active Active
- 2006-06-29 HR HR20110025T patent/HRP20110025T1/hr unknown
- 2006-06-29 US US11/997,094 patent/US8691869B2/en active Active
- 2006-07-25 AR ARP060103209A patent/AR055094A1/es unknown
-
2007
- 2007-12-19 IL IL188253A patent/IL188253A0/en not_active IP Right Cessation
-
2008
- 2008-01-04 KR KR1020087000268A patent/KR101342910B1/ko not_active Expired - Fee Related
- 2008-01-30 ZA ZA200801009A patent/ZA200801009B/xx unknown
- 2008-02-25 NO NO20080983A patent/NO20080983L/no unknown
-
2011
- 2011-01-07 CY CY20111100026T patent/CY1112023T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101227896B (zh) | 2013-02-06 |
| KR101342910B1 (ko) | 2013-12-19 |
| RU2406482C2 (ru) | 2010-12-20 |
| CN101227896A (zh) | 2008-07-23 |
| CA2616508A1 (en) | 2007-02-01 |
| ATE485033T1 (de) | 2010-11-15 |
| NZ564589A (en) | 2010-01-29 |
| HK1120414A1 (en) | 2009-04-03 |
| US8691869B2 (en) | 2014-04-08 |
| ES2354278T3 (es) | 2011-03-11 |
| JP5238499B2 (ja) | 2013-07-17 |
| IL188253A0 (en) | 2008-04-13 |
| HRP20110025T1 (hr) | 2011-03-31 |
| WO2007012539A3 (en) | 2007-04-19 |
| AU2006274098A1 (en) | 2007-02-01 |
| ZA200801009B (en) | 2008-11-26 |
| JP2009502850A (ja) | 2009-01-29 |
| PL1906938T3 (pl) | 2011-05-31 |
| US20090203759A1 (en) | 2009-08-13 |
| EP1906938B1 (en) | 2010-10-20 |
| AU2006274098B2 (en) | 2012-02-09 |
| DE602006017701D1 (de) | 2010-12-02 |
| CY1112023T1 (el) | 2015-11-04 |
| PT1906938E (pt) | 2011-01-17 |
| DK1906938T3 (da) | 2011-02-07 |
| CA2616508C (en) | 2015-02-24 |
| RU2008104505A (ru) | 2009-09-10 |
| WO2007012539A2 (en) | 2007-02-01 |
| SI1906938T1 (sl) | 2011-02-28 |
| MX2008001213A (es) | 2008-03-24 |
| EP1906938A2 (en) | 2008-04-09 |
| NO20080983L (no) | 2008-02-25 |
| KR20080028412A (ko) | 2008-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120582A1 (es) | Conjugados de insulina cristalina | |
| ES2478516T3 (es) | Microcápsulas sin formaldehído estables | |
| AR072347A1 (es) | Composiciones de complejo de ciclopropeno | |
| MX2020003316A (es) | Composición de champú compacto que contiene surfactantes libres de sulfato. | |
| PE20181493A1 (es) | Profarmaco de adrenomedulina basado en polietilenglicol y su uso | |
| MX338338B (es) | Composiciones y metodos utiles para el tratamiento de enfermedades respiratorias. | |
| ES2422267T3 (es) | Disoluciones desinfectantes concentradas de peróxido de hidrógeno | |
| AR050946A1 (es) | Composiciones para el tratamiento de la ropa. | |
| AR060152A1 (es) | Agentes herbicidas en forma de dispersiones que contienen diflufenican y flurtamona | |
| DOP2012000140A (es) | Compuestos lipopeptidos y metodos relacionados | |
| SV2008003088A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen | |
| AR076628A1 (es) | Carbohidratos | |
| AR079713A1 (es) | Una composicion detergente alcalina liquida para lavado manual de vajilla | |
| CL2011001306A1 (es) | Composicion antimicrobiana que comprende una sal de plata soluble, una alcanolamida, y/o aminoalcohol, un ph 6 o superior; composicion limpiadora que comprende un surfactante, una sal de plata soluble, una alcanolamida, y/o aminoalcohol. | |
| AR088442A1 (es) | Composiciones detergentes que comprenden sistemas surfactantes primarios que comprenden surfactantes con base en isoprenoides altamente ramificados y otros surfactantes | |
| CL2023003124A1 (es) | Anticuerpos anti-tslp modificados | |
| ES2629407T3 (es) | Soluciones acuosas que contienen un agente complejante en alta concentración | |
| BR112017003340A2 (pt) | agente antiestático, composição do agente antiestático, composição de resina antiestática e moldagem | |
| BR112013025072A2 (pt) | acopladores para ácidos graxos de cadeia média e composições desinfetantes | |
| CL2007001628A1 (es) | Composicion quimica que comprende i) kappa-2-carragenano, ii) un minimo de 70% de sodio en peso de todos los cationes en esa composicion y iii) entre 0-25% de una sal libre, con una viscosidad de 20 a 40 cps; forma solida; pelicula de gel homogenea, temorreversible; composicion de recubrimiento. | |
| UY31245A1 (es) | Formulaciones líquidas solubles de sales amónicas de quinclorac | |
| AR055094A1 (es) | Formulacion farmaceutica de nitrooxiderivados de nsaid | |
| ES2565336T3 (es) | Monoalquilsulfosuccinatos en formulaciones pesticidas y aplicaciones como hidrótropos | |
| AR068327A1 (es) | Composicion farmaceutica liquida estable a base de trazodona | |
| AR072419A1 (es) | Composicion pesticida acuosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |